Recommended for you

Dr Ireti Adejumo, expert in respiratory medicine at the University of Nottingham, presents practical steps and tips on how to effectively assess asthma control. Here Dr Adejumo discusses, the symptoms, pathophysiology and future risks of asthma, the definition of asthma control, tools to assess symptom control in asthma patients, how to assess future risk from uncontrolled asthma, what adherence and poor adherence mean for asthma patients, she ends with a practical patient example of how assessing symptom control helps in identifying the need for behaviour change in patients ultimately improving asthma management.

An expert presentation on how to achieve asthma control and management

An expert presentation on Asthma, comorbidities and special populations

Experts from the CDC present a comprehensive overview: Zika Virus-What Clinicians Need to Know, and provide responses to selected questions

This presentation deals with the phenotypes and possible endotypes of asthma. The differentiation between allergic asthma and intrinsic asthma (non-allergic asthma) will be discussed. Furthermore, the problems of neutrophilic asthma will be looked at.

In this expert presentation consultant hepatologist Dr Ahmed Elsharkawy discusses the current recommendations for patients with kidney disease and HCV. Using a case study, he explains what HCV monitoring is required in patients on renal replacement therapy and on dialysis. The HCV treatments to be offered and their evidence of efficacy is also described. Dr Elsharkawy concludes with practical take-home messages to summarize his presentation.

Dr Daniel Forton, consultant hepatologist at St George’s University Hospitals NHS Foundation Trust, London, reviews the treatment of hepatitis C, especially Direct Acting Antiviral regimes and the importance of real-world data to inform optimal selection of treatments for specific patient groups. He concludes that real-world data suggest there is still a need to tailor treatment duration with the addition of ribavirin in certain situations with certain regimes to optimise efficacy.

Professor Graham Foster, Professor of Hepatology at Queen Mary University of London, reviews the prevalance of hepatitis C among different communities as well as common treatment barriers and practial solutions. He concludes that modern-day medicine enables a variety of populations to clear viral liver disease, but highlights the challenges of engaging populations such as immigrants, MSMs and prisoners in to hepatitis C therapy.